Thryv Therapeutics
LATEST NEWS
Updates from our research programs and clinical development.
THRV-1268 Maintained a Near-Normal Ejection Fraction and Outperformed Empagliflozin Monotherapy in a Validated Model of Heart Failure; Phase 1 Studies Demonstrated Favorable Safety Profile and QTcF Shortening
Exclusive worldwide license adds a structurally distinct SGK1 inhibitor scaffold to Thryv's portfolio, with claims spanning neurodegenerative and cardiovascular indications, creating a purpose-built path toward Parkinson's disease, Alzheimer's disease, and related disorders alongside the company's advancing cardiac programs.
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited and acquired cardiometabolic diseases, today announced its participation in three upcoming prominent investor conferences in New York City.
Patient dosing has commenced in the Phase 2/3 Wave II clinical study evaluating THRV-1268 in patients with genetically confirmed Long QT Syndrome Type 2, and the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to THRV-1268 for the treatment of Long QT Syndrome Type 2 and Type 3.
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the initiation of the Wave II clinical study, a pivotal Phase 2/3 clinical research study in adults diagnosed with Long QT Syndrome Type 2 (LQTS2).
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias and cardiometabolic diseases, today announced encouraging results from a recently completed Phase 1 clinical study evaluating THRV-1268 in obese participants (NCT07186946).
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Matt Killeen, PhD, as Chief Business Officer (CBO).
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the launch of myQTwave, a first-of-its-kind, fully remote, app-based observational study designed to capture the lived experience of people with Long QT Syndrome (LQTS).
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Amy Rudolph, PhD, to its Board of Directors.
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced that new preclinical data will be presented at the American Heart Association’s Scientific Sessions 2025, taking place November 8–10 in New Orleans, Louisiana.
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced its participation in several prominent healthcare investor conferences this fall, where the company will provide updates on its pipeline and progress in precision cardiovascular medicine.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its lead compound, THRV-1268. This clearance enables Thryv to initiate the Phase 2/3 WAVE II clinical study in Long QT Syndrome (LQTS) Type 2.
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced the presentation of preclinical results demonstrating improvements in adverse cardiac remodeling beyond empagliflozin (EMPA) by reducing inflammation and fibrosis mechanisms in heart failure.
Thryv Therapeutics Inc., a clinical-stage biotechnology company, today announced that Dr. Saumya Das will present compelling new preclinical results on its lead compound, THRV-1268, at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 – September 1, 2025, in Madrid, Spain.
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced its participation in two upcoming prominent investor conferences in New York City.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Heart Rhythm Society (HRS) Annual Meeting. The conference will be held at the San Diego Convention Center from April 24-27, 2025.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Piper Sandler Virtual Cardio Day on April 1, 2025.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partners Global Healthcare Conference. The event is set to take place from March 10-12, 2025, at the W Hotel South Beach in Miami, Florida.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its attendance at the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, CA.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce the appointment of Amy Sehnert, MD, as Chief Medical Officer (CMO).
Thryv Therapeutics Inc., a biotechnology company pioneering treatments for genetic and cardiometabolic conditions, including congenital Long QT Syndrome, heart failure, and atrial fibrillation, has completed phase 1 dosing of its second SGK1 inhibitor.
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in four prominent healthcare investor conferences over the coming weeks, providing critical updates on its advancements in precision medicine.
Thryv Therapeutics Inc., a clinical-stage biotechnology company, is proud to announce its sponsorship and active participation in the 2024 International Sudden Arrhythmia Death Syndromes (SADS) Foundation Family Conference, taking place in Chicago, Illinois from November 8th to 9th, 2024.
Thryv Therapeutics Inc., a biotechnology company pioneering precision treatments for cardiovascular conditions, including congenital Long QT Syndrome, atrial fibrillation and heart failure, is proud to announce the acceptance of four abstracts for presentation at the prestigious American Heart Association’s (AHA) 2024 Annual Scientific Sessions.
Thryv Therapeutics Inc., a clinical-stage biotechnology company, received positive top-line results from the Wave I Part 2 proof-of-concept clinical study evaluating LQT-1213 for the treatment of congenital Long QT Syndrome (cLQTS) Types 2 and 3.
Thryv Therapeutics Inc. today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to LQT-1213 for the treatment of Long QT Syndrome (LQTS). LQT-1213 is a novel, first-in-class SGK1 inhibitor specifically designed to treat congenital LQTS.
Thryv Therapeutics announced today its participation in the upcoming 2024 RBC Capital Markets Private Company Virtual Conference. Thryv will attend on Tuesday, October 1st, 2024, and will sit for a fireside chat from 10:30 a.m. to 11:00 a.m. ET.
To schedule one-on-one meetings with the team, please contact admin@thryvtrx.com.
Thryv Therapeutics is pleased to announce that it will be hosting investor meetings at the Jefferies Global Healthcare Conference on Tuesday, June 4, 2024, at the Hyatt Grand Central New York.
This year’s gathering will bring together 3,000 leading executives to address near-and long-term investment opportunities as well as current trends driving healthcare in the U.S. and internationally.
To schedule a meeting with Thryv Therapeutics throughout the day, please contact admin@thryvtrx.com.
Thryv Therapeutics Inc., a biotechnology company pioneering precision treatment to treat indications including Congenital Long QT Syndrome, atrial fibrillation, and heart failure, today announced a poster presentation of SGK1 inhibition in models of Drug-Induced QT prolongation at the 2024 Heart Rhythm Society meeting in Boston, MA. This presentation will take place on Friday, May 17th, from 10:30 a.m. to 12:30 p.m. ET. The meeting will commence with a presentation by Thryv co-founder and Principal Scientific Advisor, Dr. Saumya Das, at the Stanford Biodesign New Arrhythmia Technologies Retreat in Boston, where he will discuss Small Molecules for Arrhythmia Therapy.